Previously, several studies have reported that the frequencies of tumor cells exhibiting PD-L1 expression in ESCC range from 18.4 to 79.7%, which might be attributable to the differences in the antibodies used, interpretation criteria, specimen types affected by neoadjuvant therapy, and the geographic or racial characteristics [19–25]. Here, CD274 is linked to esophageal squamous cell carcinoma.